Liberty University College of Osteopathic Medicine, Lynchburg, Virginia, USA.
MAGMA. 2020 Aug;33(4):559-568. doi: 10.1007/s10334-019-00818-3. Epub 2020 Jan 3.
To determine the feasibility of 3D TGSE PASL MRI with long inversion times to estimate CNS perfusion clearance, comparing normals to Alzheimer disease patients.
This pilot study used 3D TGSE PASL MRI with long TIs to estimate the signal clearance of labeled blood/ultra-filtrate (CSF) from brain signal averages of seven inversion times (TI) from six regions of the brain in 18 normal subjects of ages 18-70 years before and after exercise. Arterial pulse corrected signal average per TI versus TI was plotted. The slope (linear regression) indicated the clearance rate. Three subjects with mild Alzheimer disease (AD) were studied pre-exercise only.
In normals, signal decay rate variance among brain regions, age groups and post-exercise failed to demonstrate statistical significance except in middle-age group pre- to post-exercise-dominant temporal lobe. We found highly statistically significant reduced signal clearance rate in the AD group.
Signal decay in normal age groups correlates with decay of T1, thus CSF paravascular flow egresses and is inseparable from venous outflow. The AD group correlates with decay rate T1, indicating a proportion of labeled blood ultra-filtered within the brain (paravascular fluid) is retained. This provides indirect evidence of reduced paravascular clearance in AD. Further development may produce an efficient biomarker identifying neurodegenerative diseases and future treatment efficacy.
确定使用长反转时间的 3D TGSE PASL MRI 估计中枢神经系统灌注清除率的可行性,将正常人与阿尔茨海默病患者进行比较。
本研究采用 3D TGSE PASL MRI 与长 TI 来估计从脑信号平均值中标记血液/超滤液(CSF)的信号清除率,对 18 名年龄在 18-70 岁的正常受试者进行了七次反转时间(TI)的六个脑区的研究,在运动前后。绘制了动脉脉冲校正后的每个 TI 的信号平均值与 TI 的关系图。斜率(线性回归)表示清除率。仅对 3 名轻度阿尔茨海默病(AD)患者进行了运动前研究。
在正常组中,脑区、年龄组和运动后之间的信号衰减率差异无统计学意义,除了中年组在运动前至运动后颞叶优势外。我们发现 AD 组的信号清除率显著降低。
正常年龄组的信号衰减与 T1 的衰减相关,因此 CSF 沿血管周围流出,与静脉流出密不可分。AD 组与 T1 衰减率相关,表明大脑内有一部分标记的血液超滤液(血管周围液体)被保留。这提供了 AD 中血管周围清除减少的间接证据。进一步的发展可能会产生一种有效的生物标志物,用于识别神经退行性疾病和未来的治疗效果。